Literature DB >> 20652372

Suberoyl bishydroxamic acid inhibits the growth of A549 lung cancer cells via caspase-dependent apoptosis.

Bo Ra You1, Woo Hyun Park.   

Abstract

Suberoyl bishydroxamic acid (SBHA) as a histone deacetylase (HDAC) inhibitor has various cellular effects such as cell growth and apoptosis. In the present study, we evaluated the effects of SBHA on the growth and death of A549 lung cancer cells. SBHA inhibited the growth of A549 cells with an IC(50) of approximately 50 μM at 72 h in a dose-dependent manner. DNA flow cytometric analysis indicated that SBHA induced a G2/M phase arrest of the cell cycle. This agent also induced apoptosis, as evidenced by sub-G1 cells and annexin V-FITC staining cells. SBHA-induced apoptosis was accompanied by the loss of mitochondrial membrane potential (MMP; ΔΨ(m)), Bcl-2 decrease, Bax increase, and the activation of caspase-3. All of the tested caspase inhibitors significantly rescued some cells from SBHA-induced A549 cell death. However, none of the caspase inhibitors prevented the loss of MMP (ΔΨ(m)) induced by SBHA. Intracellular reactive oxygen species (ROS) levels including O(2)(•-) were increased in 50 μM SBHA-treated A549 cells. None of the caspase inhibitors attenuated ROS levels in these cells. SBHA also elevated the number of glutathione (GSH)-depleted cells in A549 cells, which was reduced by treatment with caspase inhibitors. In conclusion, this is the first report that SBHA inhibited the growth of A549 lung cancer cells via caspase-dependent apoptosis, which was related to GSH depletion rather than changes in ROS level.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20652372     DOI: 10.1007/s11010-010-0543-1

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  30 in total

Review 1.  Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs.

Authors:  C A Hassig; S L Schreiber
Journal:  Curr Opin Chem Biol       Date:  1997-10       Impact factor: 8.822

Review 2.  Histone deacetylase inhibitors in programmed cell death and cancer therapy.

Authors:  Paul A Marks; Xuejun Jiang
Journal:  Cell Cycle       Date:  2005-04-28       Impact factor: 4.534

Review 3.  Histone deacetylation : an attractive target for cancer therapy?

Authors:  Anas Al-Janadi; Sreenivasa R Chandana; Barbara A Conley
Journal:  Drugs R D       Date:  2008

4.  Apoptosis in pyrogallol-treated Calu-6 cells is correlated with the changes of intracellular GSH levels rather than ROS levels.

Authors:  Yong Hwan Han; Sung Zoo Kim; Suhn Hee Kim; Woo Hyun Park
Journal:  Lung Cancer       Date:  2007-10-24       Impact factor: 5.705

Review 5.  Histone deacetylase inhibitors in cancer therapy.

Authors:  Min-Jung Lee; Yeong Sang Kim; Shivaani Kummar; Giuseppe Giaccone; Jane B Trepel
Journal:  Curr Opin Oncol       Date:  2008-11       Impact factor: 3.645

6.  Caspase inhibitor decreases apoptosis in pyrogallol-treated lung cancer Calu-6 cells via the prevention of GSH depletion.

Authors:  Yong Hwan Han; Suhn Hee Kim; Sung Zoo Kim; Woo Hyun Park
Journal:  Int J Oncol       Date:  2008-11       Impact factor: 5.650

7.  Suberoyl bis-hydroxamic acid activates Notch-1 signaling and induces apoptosis in medullary thyroid carcinoma cells.

Authors:  Li Ning; David Yu Greenblatt; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Oncologist       Date:  2008-02

8.  De novo synthesis of glutathione is required for both entry into and progression through the cell cycle.

Authors:  M Poot; H Teubert; P S Rabinovitch; T J Kavanagh
Journal:  J Cell Physiol       Date:  1995-06       Impact factor: 6.384

Review 9.  Development of histone deacetylase inhibitors for cancer treatment.

Authors:  Douglas Marchion; Pamela Münster
Journal:  Expert Rev Anticancer Ther       Date:  2007-04       Impact factor: 4.512

Review 10.  New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.

Authors:  Shundong Cang; Yuehua Ma; Delong Liu
Journal:  J Hematol Oncol       Date:  2009-06-01       Impact factor: 17.388

View more
  7 in total

1.  Suberoyl bis-hydroxamic acid reactivates Kaposi's sarcoma-associated herpesvirus through histone acetylation and induces apoptosis in lymphoma cells.

Authors:  Shun Iida; Sohtaro Mine; Keiji Ueda; Tadaki Suzuki; Hideki Hasegawa; Harutaka Katano
Journal:  J Virol       Date:  2020-12-16       Impact factor: 5.103

2.  Reactive oxygen species, glutathione, and thioredoxin influence suberoyl bishydroxamic acid-induced apoptosis in A549 lung cancer cells.

Authors:  Bo Ra You; Suhn Hee Kim; Woo Hyun Park
Journal:  Tumour Biol       Date:  2014-12-24

3.  Histone deacetylase inhibition reduces deleterious cytokine release induced by ingenol stimulation.

Authors:  Erin T Larragoite; Racheal A Nell; Laura J Martins; Louis R Barrows; Vicente Planelles; Adam M Spivak
Journal:  Biochem Pharmacol       Date:  2021-11-18       Impact factor: 5.858

4.  Synthesis and Anticancer Potential of New Hydroxamic Acid Derivatives as Chemotherapeutic Agents.

Authors:  Işıl Nihan Korkmaz; Hasan Özdemir
Journal:  Appl Biochem Biotechnol       Date:  2022-08-02       Impact factor: 3.094

5.  Suberoyl bishydroxamic acid-induced apoptosis in HeLa cells via ROS-independent, GSH-dependent manner.

Authors:  Bo Ra You; Woo Hyun Park
Journal:  Mol Biol Rep       Date:  2012-12-27       Impact factor: 2.316

6.  Suberoyl bis-hydroxamic acid enhances cytotoxicity induced by proteasome inhibitors in breast cancer cells.

Authors:  Xinmiao Yang; Zeliang Shi; Ning Zhang; Zhouluo Ou; Shen Fu; Xichun Hu; Zhenzhou Shen
Journal:  Cancer Cell Int       Date:  2014-11-12       Impact factor: 5.722

7.  Antioxidants impair anti-tumoral effects of Vorinostat, but not anti-neoplastic effects of Vorinostat and caspase-8 downregulation.

Authors:  Laura Bergadà; Andree Yeramian; Annabel Sorolla; Xavier Matias-Guiu; Xavier Dolcet
Journal:  PLoS One       Date:  2014-03-20       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.